ADMA Biologics Inc (ADMA) Q3 2025: Everything You Need to Know Ahead of Earnings

This article first appeared on GuruFocus.

ADMA Biologics Inc (NASDAQ:ADMA) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $0.13 billion, and the earnings are expected to come in at $0.15 per share. The full year 2025's revenue is expected to be $0.51 billion, and the earnings are expected to be $0.57 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 3 Warning Sign with ADMA.

Is ADMA fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for ADMA Biologics Inc (NASDAQ:ADMA) have increased from $0.50 billion to $0.51 billion for the full year 2025 and increased from $0.63 billion to $0.64 billion for 2026 over the past 90 days. Earnings estimates have declined from $0.61 per share to $0.57 per share for the full year 2025 and declined from $0.94 per share to $0.90 per share for 2026 over the past 90 days.

In the previous quarter ending on 2025-06-30, ADMA Biologics Inc's (NASDAQ:ADMA) actual revenue was $0.12 billion, which missed analysts' revenue expectations of $0.12 billion by -0.56%. ADMA Biologics Inc's (NASDAQ:ADMA) actual earnings were $0.14 per share, which met analysts' earnings expectations. After releasing the results, ADMA Biologics Inc (NASDAQ:ADMA) was down by -9.65% in one day.

Based on the one-year price targets offered by 4 analysts, the average target price for ADMA Biologics Inc (NASDAQ:ADMA) is $27.25, with a high estimate of $32.00 and a low estimate of $17.00. The average target implies an upside of 77.29% from the current price of $15.37.

Based on GuruFocus estimates, the estimated GF Value for ADMA Biologics Inc (NASDAQ:ADMA) in one year is $13.55, suggesting a downside of -11.84% from the current price of $15.37.

Based on the consensus recommendation from 4 brokerage firms, ADMA Biologics Inc's (NASDAQ:ADMA) average brokerage recommendation is currently 1.8, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Scroll to Top